Početna › Karcinom prostate otporan na kastraciju › Kalifornija
Kliničke studije za Karcinom prostate otporan na kastraciju u državi Kalifornija
11 studija za Karcinom prostate otporan na kastraciju traži sudionike na lokacijama u državi Kalifornija.
Gradovi u državi Kalifornija
Službeni tekst studije (engleski)
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
- MemorialCare Orange Coast Medical Center, Fountain Valley
- University Of California San Diego, La Jolla
- Cancer and Blood Specialty Clinic, Los Alamitos
- i još 6
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT07225946A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
- University of California at San Diego, La Jolla
- Cedars Sinai Medical Center, Los Angeles
- Ronald Reagan UCLA Medical Center, Los Angeles
- i još 1
U tijeku regrutacijaFaza 3
Od 18 godina i više · Muškarci · Ažurirano 25. ruj 2026. · NCT07164443A Study in Patients With Metastatic Castration-Resistant Prostate Cancer
- START Los Angeles, Los Angeles
U tijeku regrutacijaFaza 1
Od 18 godina i više · Muškarci · Ažurirano 24. ruj 2026. · NCT07719361A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
- UCLA Hematology & Oncology ( Site 0003), Los Angeles
- University of California-Irvine Medical Center ( Site 0016), Orange
- UCSF Medical Center at Mission Bay ( Site 0034), San Francisco
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 17. ruj 2026. · NCT06863272Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
- UCSD Moores Cancer Center ( Site 0039), La Jolla
- UCLA Hematology/Oncology - Santa Monica ( Site 0044), Los Angeles
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 17. ruj 2026. · NCT06353386Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer
- UCI Health Chao Family Comprehensive Cancer Center, Orange
- Investigational Site Number: 403, Palo Alto
U tijeku regrutacijaFaza 1
Od 18 godina i više · Muškarci · Ažurirano 10. ruj 2026. · NCT05997615Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
- USC Norris Comprehensive Cancer Center, Los Angeles
- UCLA Department of Medicine, Los Angeles
- Hoag Memorial Hospital Presbyterian, Newport Beach
- i još 2
U tijeku regrutacijaFaza 1
Od 18 do 100 godina · Muškarci · Ažurirano 13. kol 2026. · NCT05519449A Study of MGC026 in Participants With Advanced Solid Tumors
- The Angeles Clinic and Research Institute, Los Angeles
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 11. kol 2026. · NCT06242470A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
- Stanford Cancer Center, Palo Alto
U tijeku regrutacijaFaza 1
Od 18 godina i više · Muškarci · Ažurirano 10. kol 2026. · NCT0606784164Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)
- Stanford Cancer Institute, Stanford
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Muškarci · Ažurirano 6. svi 2026. · NCT0486860418F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer
- VA Greater Los Angeles Healthcare System, Los Angeles
U tijeku regrutacijaFaza 4
Od 18 godina i više · Muškarci · Ažurirano 27. stu 2024. · NCT06706921Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.